Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 101 to 150 of 410 results for stroke

  1. For people with different causes of shoulder pain after stroke, what is the clinical and cost effectiveness of interventions in reducing pain?

    Question For people with different causes of shoulder pain after stroke, what is the clinical and cost effectiveness of interventions...

  2. Type 2 diabetes: prevention in people at high risk (PH38)

    This guideline covers how to identify adults at high risk of type 2 diabetes. It aims to remind practitioners that age is no barrier to being at high risk of, or developing, the condition. It also aims to help them provide those at high risk with an effective and appropriate intensive lifestyle-change programme to prevent or delay the onset of type 2 diabetes. The recommendations in this guideline can be used alongside the NHS Health Check programme .

  3. Avoidance of aspiration pneumonia: Does the withdrawal of oral liquids or the use of modified (thickened) oral fluids prevent the development of aspiration pneumonia after an acute stroke?

    pneumonia after an acute stroke? Any explanatory notes(if applicable) People with dysphagia after an acute stroke are at...

  4. Safety and efficacy of carotid stenting: What is the safety and efficacy of carotid stenting compared with carotid endarterectomy when these procedures are carried out within 2 weeks of TIA or recovered stroke?

    when these procedures are carried out within 2 weeks of TIA or recovered stroke? Any explanatory notes(if applicable) Carotid stenting...

  5. Stroke and ischaemic attack: blood pressure (80 years and over) (IND244)

    This indicator covers the percentage of patients aged 80 years or over with a history of stroke or TIA in whom the last blood pressure reading (measured in the preceding 12 months) is less than 145/85 mmHg if using ambulatory or home monitoring, or less than 150/90 mmHg if monitored in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM228

  6. Stroke and ischaemic attack: blood pressure (79 years and under) (IND243)

    This indicator covers the percentage of patients aged 79 years or under with a history of stroke or TIA in whom the last blood pressure reading (measured in the preceding 12 months) is less than 135/85 mmHg if using ambulatory or home monitoring, or less than 140/90 mmHg if monitored in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM227

  7. Tinnitus: assessment and management (NG155)

    This guideline covers the assessment, investigation and management of tinnitus in primary, community and secondary care. It offers advice to healthcare professionals on supporting people presenting with tinnitus and on when to refer for specialist assessment and management.

  8. Dementia. Patient decision aid on antipsychotic medicines for treating agitation, aggression and distress in people living with dementia

    explain further. The most serious side effects include an increased risk of stroke and an increased risk of death. The diagrams on pages...

  9. Artificial intelligence for analysing CT brain scans (MIB207)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing CT brain scans .

  10. Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)

    Evidence-based recommendations on hybrid closed loop systems for managing blood glucose levels in type 1 diabetes.

  11. ReStore Soft Exo-Suit for gait rehabilitation (MIB239)

    NICE has developed a medtech innovation briefing (MIB) on ReStore Soft Exo-Suit for gait rehabilitation .

  12. Endovascular closure of atrial septal defect (HTG58)

    Evidence-based recommendations on endovascular closure of atrial septal defect. This involves inserting a small blocking device into the heart, which is gently inflated to close the hole.

  13. Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care (HTG508)

    Evidence-based recommendations on lead-I electrocardiogram (ECG) devices (imPulse, Kardia Mobile, MyDiagnostick and Zenicor-ECG) for detecting symptomatic atrial fibrillation using single time point testing in primary care.

  14. Coil embolisation of ruptured intracranial aneurysms (HTG64)

    Evidence-based recommendations on coil embolisation of ruptured intracranial aneurysms. This involves passing a thin tube through the body to place coils inside the aneurysm.

  15. Atrial fibrillation: review of anticoagulation (IND169)

    This indicator covers the percentage of patients with atrial fibrillation, currently treated with an anticoagulant, who have had a review in the preceding 12 months which included: assessment of stroke/VTE risk; assessment of bleeding risk; assessment of renal function, creatinine clearance, FBC and LFTs as appropriate for their anticoagulation therapy; any adverse effects related to anticoagulation; assessment of compliance; choice of anticoagulant. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM147

  16. KardiaMobile for detecting atrial fibrillation (HTG606)

    Evidence-based recommendations on KardiaMobile for detecting atrial fibrillation.

  17. Diabetes: complications (IND9)

    This indicator covers the proportion of adults with a diagnosis of diabetes who have a recording of myocardial infarction (MI), stroke and/or end stage kidney disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG12

  18. Spectra Optia for automatic red blood cell exchange in people with sickle cell disease (HTG405)

    Evidence-based recommendations on Spectra Optia for automated red blood cell exchange in people with sickle cell disease.

  19. What is the clinical and cost effectiveness of computer-based tools to treat problems with speech (dysarthria) and all domains of language (aphasia) for people with communication difficulties after stroke?

    domains of language (aphasia) for people with communication difficulties after stroke? Any explanatory notes(if applicable) For a short...

  20. Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management (NG228)

    This guideline covers diagnosing and treating an aneurysmal (caused by a ruptured aneurysm) subarachnoid haemorrhage and its complications. It provides recommendations to improve diagnosis and ensure that the most effective treatments are offered. It includes guidance on follow-up care and information for people (aged 16 and over) who have had an aneurysmal subarachnoid haemorrhage, their families and carers.

  21. Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms (HTG287)

    Evidence-based recommendations on the Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms.

  22. Implanting a baroreceptor stimulation device for resistant hypertension (HTG387)

    Evidence-based recommendations on implanting a baroreceptor stimulation device for resistant hypertension. This involves using electrical impulses from the device that stimulate baroreceptors to help the body lower blood pressure.

  23. Patient decision aids

    disease and stroke) How do I control my blood pressure? Lifestyle options and choice of medicines Should I take a statin? Surgery after...

  24. Board members

    Our board sets out our strategic priorities and policies. It has 2 sub-committees, the audit and risk assurance committee and the remuneration committee.

  25. Angina and coronary heart disease: anti-platelet or anticoagulation (IND132)

    This indicator covers the percentage of patients with coronary heart disease with a record in the preceding 12 months that aspirin, an alternative anti-platelet therapy, or an anti-coagulant is being taken. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM88.

  26. Diabetes: T1DM and lipid-lowering therapies (IND277)

    This indicator covers the percentage of patients with type 1 diabetes aged over 40 years (excluding people with a history of haemorrhagic stroke) who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  27. Deep brain stimulation for Parkinson's disease (HTG7)

    Evidence-based recommendations on deep brain stimulation for Parkinson's disease. This involves planting electrodes into the brain and generating electrical currents to reduce the problems caused by Parkinson's disease.

  28. Rheumatoid arthritis: cardiovascular risk assessment (IND108)

    This indicator covers the percentage of patients with rheumatoid arthritis (RA) aged 30 to 84 years who have had a cardiovascular risk assessment using a cardiovascular disease (CVD) risk assessment tool adjusted for RA in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM56

  29. Into practice resources

    Resources, case studies and patient decision aids to show how you can use evidence to improve care and services

  30. Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)

    Evidence-based recommendations on edoxaban (Lixiana) for treating deep vein thrombosis and pulmonary embolism in adults and preventing them happening again.

  31. Acute upper gastrointestinal bleeding in over 16s: management (CG141)

    This guideline covers how upper gastrointestinal bleeding can be effectively managed in adults and young people aged 16 years and older. It aims to identify which diagnostic and therapeutic steps are useful so hospitals can develop a structure in which clinical teams can deliver an optimum service for people who develop this condition.

  32. Hypertension: lifestyle advice (IND146)

    This indicator covers the percentage of patients diagnosed with hypertension (diagnosed on or after 1 April 2009) who are given lifestyle advice in the preceding 12 months for: smoking cessation, safe alcohol consumption and healthy diet. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM112

  33. Smoking: smoking status for people with long-term conditions (IND97)

    This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM38

  34. ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)

    NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot

  35. Short-term circulatory support with left ventricular assist devices as a bridge to cardiac transplantation or recovery (HTG115)

    Evidence-based recommendations on short-term circulatory support with left ventricular assist devices (LVAD) as a bridge to heart transplantation or recovery. This involves inserting a mechanical device into the chest to help the heart pump blood around the body.

  36. Weight management: BMI recording (long term conditions) (IND320)

    This indicator covers the percentage of patients with coronary heart disease, stroke or TIA, diabetes, at high risk of developing type 2 diabetes, hypertension, peripheral arterial disease, heart failure, COPD, dyslipidaemia, learning disability, obstructive sleep apnoea, schizophrenia, bipolar disorder or other psychoses who have had a BMI recorded in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  37. Peripheral arterial disease (QS52)

    This quality standard covers diagnosing and managing lower limb peripheral arterial disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

  38. High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery (HTG119)

    Evidence-based recommendations on high-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery. This involves using focused ultrasound energy to destroy cardiac tissue and disrupt abnormal electrical impulses.

  39. E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta (HTG326)

    Evidence-based recommendations on the E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta.

  40. Key question: effective

    This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.

  41. Migalastat for treating Fabry disease (HST4)

    Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16.

  42. Ticagrelor for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack [ID2689]

    Discontinued Reference number: GID-TA10663

  43. Thoracoscopic epicardial radiofrequency ablation for atrial fibrillation (HTG180)

    Evidence-based recommendations on thoracoscopic epicardial radiofrequency ablation for atrial fibrillation. This involves using heat to destroy the selected areas of the heart to prevent the occurrence or conduction of abnormal electrical activity.

  44. Secondary prevention after a myocardial infarction (QS99)

    This quality standard covers preventing further cardiovascular disease after a myocardial infarction (heart attack). It includes assessment and cardiac rehabilitation. It describes high-quality care in priority areas for improvement.

  45. Services for older people

    Jamaican café, where he eats his main meal of the day. However since having a stroke he lacks the confidence to leave the house. His...

  46. Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis (MIB93)

    NICE has developed a medtech innovation briefing (MIB) on the Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis .

  47. Colorectal cancer . Patient decision aid on Lynch syndrome: should I take aspirin to reduce my chance of getting bowel cancer?

    people in 10,000 do not). Aspirin can also make a type of stroke known as haemorrhagic stroke (bleeding inside the brain)...

  48. Laser-assisted cerebral vascular anastomosis without temporary arterial occlusion (HTG161)

    Evidence-based recommendations on laser-assisted cerebral vascular anastomosis without temporary arterial occlusion. This involves using a special laser device to create a bypass without the need to temporarily interrupt the blood flow to the brain.